Deltex Medical’s TrueVue oesophageal Doppler monitoring technology (ODM+) has become a valued friend for many an anaesthetist in critical care or surgery. A combined focus on the two buzzwords, “outcomes” and “evidence” point to only one solution, ODM+. Its capacity to monitor blood flow as it leaves the heart makes ODM+ the most accurate and real-time haemodynamic management technology. This also explains why ODM+ is uniquely supported by multiple randomised controlled trials.
Until recently Deltex was only able to address anaesthetised or heavily sedated patients. Now though, with its TrueVue system approach, Deltex has extended the reach of its product portfolio to include a suite of "best-in-class" solutions for haemodynamic monitoring across all clinical settings.
Why haemodynamic monitoring?
Keeping the patient in their haemodynamic sweet spot is widely recognised as being vital in maintaining perfusion of the vital organs. The kidneys, for example, can be damaged by too much or too little circulating fluid (hyper/hypovolaemia respectively). Studies agree that 8% of major surgeries result in Acute Kidney Injury… that’s an 8% chance of acquiring a serious condition in hospital that you didn’t have when you arrived!
The heart of the matter
ODM+ involves the insertion of a probe down the patient’s oesophagus. The probe tip uses ultrasound to deliver an instantaneous, highly accurate picture of the blood flow in the aorta. The result is a unique and incredible window into the patient's haemodynamic status. From the performance of the heart to the amount of circulating blood volume, this is a view of the internal physiology that can guide clinical decisions about administration of fluid and vasoactive drugs. By gaining its data directly from source, ODM+ does not “back-calculate” from peripheral blood pressure readings. As such the information is “real time and real”, never masked or clouded by factors such as vasodilation or vasoconstriction.
COVID-19 Critical Care
COVID-19, while essentially a respiratory disease, brings with it circulatory consequences. A high incidence of Acute Kidney Injury (around 30%) means maintenance of adequate organ perfusion a high priority. ODM+ is uniquely capable of delivering constant haemodynamic monitoring of ventilated patients, providing critical care teams with the ultimate means of optimising this vital parameter. Indeed ODM+ is considered the “house” monitoring solution at many of the world’s leading critical care units.
CEO Comments
Deltex CEO Andy Mears comments; “Even after all these years the opportunity remains significant and we’re committed to helping clinicians to see the light when it comes to haemodynamic management. Resistance to adoption comes from the fact that it’s an extra demand on the anaesthetist during a surgical procedure or in critical care. However an experienced operator can quickly achieve probe insertion and focusing. We’re totally committed to the cause and here to help. And in COVID-19 care Deltex is extremely proud to be able to play a part at what is a difficult and challenging time for patients and care providers.”